Table 2.
Parameter | Groups | 2-Year OS (%) | 5-Year OS (%) | 10-Year OS (%) | χ2 Test-Value | p-value |
---|---|---|---|---|---|---|
Age | 19–49 | 88 | 72 | 72 | 19.646 | 0.002 |
50–61 | 78 | 75 | 13 | |||
62–70 | 62 | 53 | 16 | |||
71–88 | 44 | 23 | 23 | |||
Gender | Female | 66 | 51 | 24 | 0.864 | 0.387 |
Male | 70 | 58 | 38 | |||
WHO | 0 | 91 | 82 | 82 | 38.469 | <0.001 |
1 | 63 | 50 | 17 | |||
2 | 28 | 6 | 0 | |||
3 | 0 | 0 | 0 | |||
Location | Parotid | 75 | 67 | 39 | 1.975 | 0.048 |
Submandibular | 63 | 45 | 24 | |||
Clinical Nerve palsy | Yes | 39 | 27 | 19 | 3.797 | <0.001 |
No | 79 | 66 | 34 | |||
Radicality | R0 | 75 | 60 | 33 | 8.200 | 0.017 |
R1 | 64 | 56 | 35 | |||
R2 | 45 | 24 | 12 | |||
Nerve palsy after surgery | Yes | 43 | 27 | 17 | 4.114 | <0.001 |
No | 80 | 68 | 33 | |||
Histopathological type | Squamous | 41 | 32 | 0 | 13.646 | 0.018 |
Adenocarcinoma | 84 | 61 | 33 | |||
Cystic adenoid carcinoma | 77 | 70 | 35 | |||
Undifferentiated | 67 | 32 | 19 | |||
Acinic | 83 | 72 | 56 | |||
Other | 74 | 64 | 45 | |||
Neuroinvasion | Yes | 50 | 34 | 20 | 3.248 | 0.001 |
No | 77 | 65 | 36 | |||
Angioinvasion | Yes | 55 | 41 | 40 | 1.150 | 0.250 |
No | 70 | 57 | 31 | |||
Stage | I | 94 | 94 | 51 | 23.219 | <0.001 |
II | 85 | 74 | 44 | |||
III | 62 | 58 | 26 | |||
IVab | 52 | 29 | 25 | |||
T | 1 | 96 | 96 | 51 | 30.977 | <0.001 |
2 | 81 | 67 | 42 | |||
3 | 61 | 53 | 24 | |||
4 | 42 | 19 | 19 | |||
N | positive | 48 | 28 | 16 | 4.230 | <0.001 |
negative | 79 | 69 | 40 | |||
Time | <9 weeks | 76 | 65 | 42 | 2.295 | 0.022 |
≥9 weeks | 60 | 43 | 19 | |||
Technique of RT | 2D | 29 | 14 | 14 | 4.036 | <0.001 |
3D | 69 | 59 | 34 | |||
IMRT | 83 | 67 | 31 | |||
Dose | <60Gy | 35 | 26 | 9 | 26.350 | <0.001 |
≥60Gy | 78 | 62 | 37 | |||
CHT | yes | 72 | 60 | 30 | 0.880 | 0.929 |
no | 68 | 54 | 30 | |||
Hemoglobin level | <12.5 mg/dL | 40 | 40 | N/A | 2.253 | 0.024 |
≥12.5 mg/dL | 83 | 72 | N/A | |||
Tumor volume | ≤ 10 cm3 | 95 | 95 | 51 | 11.725 | 0.008 |
10.1–50 cm3 | 85 | 65 | N/A | |||
50.1–100 cm3 | 63 | 51 | 16 | |||
>100 cm3 | 46 | 37 | N/A | |||
Irradiation area | Only surgical bed with margin | 88 | 75 | 63 | 15.561 | 0.001 |
Surgical bed + lnd. group I-II | 78 | 63 | 39 | |||
Surgical bed + unilateral lnd. | 67 | 56 | 24 | |||
Surgical bed + bilateral lnd | 43 | 23 | 8 | |||
Tumor bed volume (dose ≥ 60Gy) | ≤100 cm3 | 94 | 94 | 50 | 10.050 | 0.019 |
100.1–200 cm3 | 84 | 65 | 39 | |||
200.1–300 cm3 | 76 | 63 | 0 | |||
>300 cm3 | 50 | 37 | N/A | |||
Elective area volume (dose ≥ 50Gy) | ≤150 cm3 | 90 | 83 | 43 | 10.725 | 0.029 |
150.1–300 cm3 | 65 | 46 | 0 | |||
300.1–450 cm3 | 65 | 64 | N/A | |||
450.1–600 cm3 | 62 | 33 | 0 | |||
>600 cm3 | 67 | 33 | N/A |
Note: Statistically significant results in bold.
Abbreviations: p, significance level; R0, radical surgery; R1, non-radical microscopic surgery; R2, non-radical macroscopic surgery; RT, radiotherapy; CHT, chemotherapy; RT, radiotherapy; 2D, two-dimensional planning; 3D, three-dimensional planning; IMRT, planning with intensity-modulated radiation therapy